Form 4: ClearPoint Neuro Director Girin Acquires Restricted Stock Units
SEC Form 4 Filing
Director Pascal E. R. Girin acquired 21,093 restricted stock units in ClearPoint Neuro, Inc.
Summary
- On May 16, 2024, Pascal E. R. Girin, a director of ClearPoint Neuro, Inc. (CLPT), acquired 21,093 restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one share of CLPT common stock.
- The RSUs vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders.
- Following the transaction, Girin directly owns 21,093 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock units being granted to a director.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of restricted stock units, which is a common form of equity compensation.
Stakeholder Impact
- The acquisition of restricted stock units by a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of transaction: Pascal E. R. Girin acquired 21,093 restricted stock units. |
| 05/17/2024 | Date of Form 4 filing. |
| 05/16/2025 | First possible vesting date of the restricted stock units (one year after grant date). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.